Recent studies suggest that tumor-derived microvesicles (MV) act as a vehicle for exchange of genetic information between tumor and stromal cells, engendering a favorable microenvironment for cancer development. Within the tumor mass, all cell types may contribute to MV shedding, but specific contributions to tumor progression have yet to be established. Here we report that a subset of tumor-initiating cells expressing the mesenchymal stem cell marker CD105 in human renal cell carcinoma releases MVs that trigger angiogenesis and promote the formation of a premetastatic niche. MVs derived only from CD105-positive cancer stem cells conferred an activated angiogenic phenotype to normal human endothelial cells, stimulating their growth and vessel formation after in vivo implantation in immunocompromised severe combined immunodeficient (SCID) mice. Furthermore, treating SCID mice with MVs shed from CD105-positive cells greatly enhanced lung metastases induced by i.v. injection of renal carcinoma cells. Molecular characterization of CD105-positive MVs defines a set of proangiogenic mRNAs and microRNAs implicated in tumor progression and metastases. Our results define a specific source of cancer stem cell-derived MVs that contribute to triggering the angiogenic switch and coordinating metastatic diffusion during tumor progression. Cancer Res; 71(15); 5346-56. Ó2011 AACR.
Introduction
Recent studies showed that exosomes/microvesicles (MV) released by cells act as mediator of intercellular communications (1) (2) (3) . Tumor cells produce large amount of MVs that may enter in the circulation and in other biological fluids (4, 5) . It has been suggested that MVs, due to their pleiotropic effect, could be involved in cancer development, progression, and formation of the premetastatic niche (6) . MVs contain mRNAs, microRNAs (miRNA), and proteins that could be transferred to target cells inducing epigenetic changes (7) (8) (9) (10) . Moreover, tumor-derived MVs may transport to neighboring cells, the products of oncogenes (11) . Emerging evidence suggests that, in cancer patients, circulating miRNAs are stable in blood, probably due to their incorporation in exosomes/microvesicles, allowing their use as novel diagnostic markers (12) .
It is generally recognized that tumors contain a heterogeneous population of cells with different proliferation and differentiation potential. The majority of cells that form tumors are designated to differentiate and ultimately to stop dividing. At variance, a minor population of cells, defined as cancer stem cells or tumor-initiating cells, possess selfrenewal capability and can induce tumors in immunocompromised animals (13) . Recently, we identified in human renal cell carcinoma a subset of tumor-initiating cells expressing the mesenchymal stem cell marker CD105 that display stem cell properties, such as clonogenic ability, expression of Nestin, Nanog, and Oct3-4 stem cell markers, and lack of epithelial differentiation markers (14) . This CD105 þ population has the capacity to generate epithelial and endothelial cells and serially transplantable tumors in vivo (14) . Previous studies showed that normal stem cells are an abundant source of MVs that may act as paracrine mediators by a horizontal transfer of genetic information (7, 8, 15) .
The aim of the present study was to evaluate whether MVs released by CD105
þ cancer stem cells of renal carcinomas may modify tumor microenvironment by triggering angiogenesis and may favor the formation of a premetastatic niche.
Material and Methods

Cell culture
Human umbilical vein endothelial cells (HUVEC) were obtained and characterized as previously described (8) .
CD105
þ cancer stem cells, 3 deriving CD105 þ clones, CD105 À tumor cells, and unsorted tumor cells were previously isolated and characterized (14) . Briefly, cell suspension obtained from 5 specimens of renal carcinomas of patients undergoing radical nephrectomy with informed consent were either used to generate unsorted tumor cells or sorted by anti-CD105 magnetic beads (MACS system; Miltenyi Biotec; ref. 14) .
To avoid the presence of nonneoplastic contaminating cells, CD105 þ cancer stem cells either were grown in expansion medium without serum (14) or were cloned. Three clones originating from 3 different renal cell carcinomas were used. The CD105 À population could not generate clones. The CD105 þ clones and the total CD105 þ cell population were negative for the endothelial or hematopoietic markers CD31, VEGF receptor (VEGFR) 2, and CD45. In addition, they showed cancer stem cells properties as expression of stem cell markers and lack of differentiative markers, ability to grow in spheres, and the ability to initiate tumors and generate serially transplantable tumors with a number of cells as few as 100 cells per mouse (Supplementary Table S1 ). All cell types were thawed, used within 2 months, and the phenotype was characterized by fluorescence-activated cell-sorting (FACS) analysis and immunofluorescence immediately before the generation of MVs. The previously described (16) K1 renal tumor cell line was thawed and characterized by FACS immediately before their use for metastases generation.
Isolation and characterization of MVs
MVs were obtained from cell supernatants by ultracentrifugation as previously described (8) . The protein content of MV preparations was quantified by Bradford method (Bio-Rad). In selected experiments, MVs were labeled with the red PKH26 dye (Sigma). The mean diameter of MVs and zeta potential were determined using a Malvern dynamic light-scattering spectrophotometer (Malvern Zetasizer 3000HS) and by transmission electron microscopy (17) . Cytofluorimetric analysis was carried out as described (17) , using the following fluorescein isothiocyanate (FITC)-or phycoerythrin (PE)-conjugated antibodies: CD44 (Dakocytomation), CD73, and CD29 (BD Biosciences), CD105, a5-integrin, a6-integrin, and HLA class I (BioLegend). FITC or PE mouse isotypic IgG (Dakocytomation) were used as controls. Beads of different sizes (1, 2, and 4 mm; Invitrogen) were used as size markers. In selected experiments, CD105
þ MVs derived from cloned CD105 þ cancer stem cells were treated with 1 U/mL RNase (Ambion) for 3 hours at 37 C (RNase CD105 þ MV; refs.
9, 10). After RNase treatment, the reaction was stopped by the addition of 10 U/mL RNase inhibitor (Ambion) and MVs were washed by ultracentrifugation. The efficacy of RNase treatment was evaluated by MV RNA analyses by Agilent 2100 bioanalyzer (Agilent Technologies) and by 0.6% agarose gel electrophoresis.
mRNA analysis RNA from MVs was isolated using the RNAqueous Micro Kit (Ambion). RNA was quantified spectrophotometrically (Nanodrop ND-1000), and its quality was assessed by Agilent 2100 Bioanalyzer. mRNA expression levels were analyzed using the RT 2 Profiler PCR array system (SABiosciences- 5 per well), labeled with CSFE, were added to the endothelial monolayer. The adhesion assay in static conditions was evaluated after 6 hours. After washings, cells adherent to HUVECs were counted by fluorescence microscopy (magnification Â 200) in 10 fields and expressed as mean AE SD of cells per field.
In vivo angiogenesis
Animal experiments were carried out according to the guidelines for the care and use of research animals and were approved by the local Ethics Committee. HUVEC, prestimulated with or without 70 mg MVs, were implanted subcutaneously into severe combined immunodeficient (SCID) mice (Charles River) within Matrigel (22) . At day 10, mice were sacrificed and the Matrigel plug was recovered. Angiogenesis was calculated as the mean AE SD of the number of vessels with red cells inside per total area of hematoxylin and eosin-stained sections. Immunohistochemistry was carried out using anti-HLA class I (Santa Cruz Biotechnology) and anti-von Willebrand factor (vWF; Dakocytomation) antibody.
In vivo metastasis SCID mice were injected intravenously daily for 5 days with 70 mg of MVs in 100 mL PBS. On day 5, mice received an i.v. injection into the tail vein of 6 Â 10 5 renal K1 tumor cells. Mice were sacrificed after 5 weeks, and organs (lung, spleen, liver, and kidney) were collected for histology. Lung metastases were counted in 5 nonsequential serial sections; results were expressed as mean AE SD of metastasis per lung (23 (Fig. 1C and D) Table S3 ). We carried out the functional characterization of the gene target list searching for GO keywords enrichment and we found a strong overrepresentation of terms belonging to crucial biological processes such as transcription, metabolic process, nucleic acid binding, cell adhesion molecules, and regulation of cell proliferation ( Fig. 2C and Supplementary (Fig. 3B) , as well as the enhanced invasion, apoptosis resistance, and adhesion properties (Fig. 4) , suggesting a role of RNA molecular species carried by MVs.
In vivo effects of CD105
þ MVs
To evaluate whether CD105 þ MVs were able to stimulate angiogenesis in vivo, we subcutaneously injected MV-stimulated HUVECs within Matrigel in SCID mice. CD105 þ MVs from cloned cancer stem cell preparations stimulated the growth of HUVECs that formed dense clusters containing small vessels organized into patent capillaries connected with the murine vasculature and into large aneurismatic structures (Fig. 5A) . The cells grew into Matrigel, and the vessels expressed the endothelial marker vWF and their human nature was shown by staining for HLA class I (Fig. 5B ). HUVECs challenged with vehicle or CD105 À MVs or RNase CD105 þ MVs did not organize or proliferate into the Matrigel. MVs from unsorted tumor cells induced HUVEC proliferation and organization into small vessels, but the extent of angiogenesis was significantly lower than that induced by CD105 þ MVs (Fig. 5C ).
To evaluate whether CD105 þ MVs contribute to establish a premetastatic niche, we intravenously injected SCID mice for 5 days with 70 mg of MVs, followed by i.v. injection of 6 Â 10 5 renal tumor cells. After 5 weeks, organs were recovered (liver, spleen, kidney, and lung) and the incidence of metastasis was evaluated. Metastases clearly detectable were found only in lungs (Fig. 6A) . The number of metastases induced by renal tumor cells was very low in mice injected with vehicle alone or with CD105 À MVs or RNase CD105 þ MVs, whereas a significant increase in the number of metastases was observed in mice pretreated with CD105 þ MVs or MVs from unsorted tumor cells. However, CD105 þ MVs were significantly more efficient in inducing metastasis than unsorted tumor MVs (Fig. 6A) . To evaluate whether the administration of MVs modify lung microenvironment, the expression of VEGFR1, VEGF, MMP9, and MMP2 was studied. By cytofluorimetric analysis, VEGFR1 expression in CD146 þ -sorted lung endothelial cells was enhanced by CD105 þ MVs but not by CD105 À MVs (Fig. 6B) . By qRT-PCR, CD105 þ MVs, but not CD105 À MVs, significantly enhanced MMP9 expression in total lung tissue and VEGF and MMP2 in sorted lung endothelial cells (Fig. 6C) . The enhanced expression of MMP9 and MMP2 in lung after treatment with CD105 þ MVs was confirmed by immunohistochemistry (Fig. 6D) . MMP2 staining was mainly confined to lung vessels, whereas that of MMP9 was more diffuse and the alveolar epithelial cells were positive.
Discussion
Previous studies showed an angiogenic potential of MVs derived from tumors but did not characterize the cells of origin (11, (24) (25) (26) . Herein, we showed that in renal cancer, the MVs that retain the angiogenic properties were those that were derived from cancer stem cells. Indeed, MVs released from cancer stem cells induced in vitro and in vivo angiogenesis and favored lung metastasis. These properties were ascribed only to the MVs released from the CD105 þ cell fraction, as those derived from the CD105 À tumor cells were ineffective. Indeed, CD105 þ MVs contained proangiogenic mRNAs and miRNAs that may be involved in tumor progression and metastases. Recently, circulating MVs were described in patients with various tumors (27) (28) (29) (30) (31) (32) , suggesting that they may serve as a diagnostic and prognostic tool (33) (34) (35) . In the context of cancer, several studies pointed out the potential role of tumor-derived MVs in the interaction with stromal cells and in the formation of premetastatic niche (36) (37) (38) (39) . The potential of MVs to reprogram recipient cells was first established by Ratajczak and colleagues (7) . Several subsequent studies indicate that mRNA delivered by MVs can be translated into the corresponding proteins by target cells (8, 9, 40) .
In the present study, we investigated whether MVs derived from cancer stem cells possess biological activities that may account for the induction of a favorable environment for tumor growth and invasion. We found that MVs derived from MVs. The proangiogenic effect of CD105 þ MVs can be ascribed to their ability to induce endothelial cell growth, organization, invasion of matrix, and resistance to apoptosis. An angiogenic effect of MVs was previously described for MVs derived from unfractionated tumor cells of lung cancer, ovarian cancer, and glioblastoma, as well as from some tumor cell lines (11, 25, 26, 33) . Beside mRNAs, MVs were shown to contain and to deliver functional miRNAs to target cells (9, 20 and miR-141 that were described significantly upregulated in patients with ovarian (28, 41) , colorectal (42) , and prostate cancer (43) , respectively. These miRNAs were suggested as marker of unfavorable prognosis (44) . In addition, we detected several miRNAs such as miR-29a, miR-650, and miR-151 that were associated with tumor invasion and metastases (45) (46) (47) . Moreover, miR-19b, miR-29c, and miR-151 were observed upregulated in renal carcinomas in comparison with normal renal tissue (48) and they were significantly enriched within miRNAs present in CD105 þ MVs.
It has been recently suggested that tumor-derived MVs may contribute to the formation of a premetastatic niche (37, 38 containing endothelial cells and a small population of both leukocytes and MMP9 in the whole lung. Previous studies showed that these factors are involved in the generation of lung premetastatic niche (49, 50) . Our results confirm that MVs create a receptive microenvironment to coordinate metastatic diffusion (37) and identify the specific contribution of MVs derived from cancer stem cells. A recent study indicated that tumor stem cells not only initiate tumors but may also promote metastases in virtue of their peculiar content of tumorigenic miRNAs (46) . MVs may transfer products of oncogenes to bystander cells, inducing changes in their phenotype (11) . The result of the present study suggests that the RNA content of MVs plays a critical role, as the RNase treatment of MVs significantly inhibited the in vitro and in particular the in vivo biological effects of CD105 þ MVs. This suggests that the effects of CD105 þ MVs could be, at least in part, accounted for epigenetic changes induced by transfer of mRNAs and/or miRNAs.
In conclusion, the results of the present study suggest that, in renal cancer, the MVs that favor tumor growth and invasion were those that were derived from the cancer stem cells rather than from the whole tumor cell population. These MVs by enhancing tumor vascularization and by contributing to the establishment of a premetastatic niche may sustain an unfavorable outcome of the tumor.
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